Ceftriaxone Resistance in Campylobacter Gastroenteritis.
| Autor: | Hsu MD; College of Medicine, California Northstate University, Elk Grove, USA., Ta APD; College of Medicine, California Northstate University, Elk Grove, USA., Iwamoto S; College of Medicine, California Northstate University, Elk Grove, USA., Leo A; College of Medicine, California Northstate University, Elk Grove, USA., Chu G; Internal Medicine, Kaiser South Sacramento, Sacramento, USA.; College of Medicine, California Northstate University, Elk Grove, USA. |
|---|---|
| Jazyk: | angličtina |
| Zdroj: | Cureus [Cureus] 2023 Dec 16; Vol. 15 (12), pp. e50632. Date of Electronic Publication: 2023 Dec 16 (Print Publication: 2023). |
| DOI: | 10.7759/cureus.50632 |
| Abstrakt: | Annually, millions of people worldwide are exposed to Campylobacter, a species of bacteria that commonly causes gastroenteritis and in cases of immunocompromised individuals, can also lead to life-threatening complications. After stool cultures are obtained, the usual treatment for infectious diarrhea involves metronidazole and quinolones such as ciprofloxacin or levofloxacin. Quinolones are a family of broad-spectrum antibiotics known to be effective against various gram-negative infections that also include Campylobacter jejuni (C. jejuni). However, due to adverse side effects and bacterial resistance risks that may exist with medication use, they are no longer used as a first line. Our patient, initially treated with ceftriaxone for symptoms resembling bacterial meningitis, pneumonia, and infectious diarrhea, showed minimal to no improvement. Subsequent cerebral spinal fluid (CSF) ruled out meningitis while stool studies confirmed C. jejuni as the causative agent. A switch to levofloxacin resulted in a noticeable improvement in the patient's condition. This case emphasizes the importance of considering changes in antibiotic regimen from ceftriaxone to quinolones when faced with persistent infectious diarrhea, due to the high prevalence of ceftriaxone resistance in C. jejuni infections. Competing Interests: The authors have declared that no competing interests exist. (Copyright © 2023, Hsu et al.) |
| Databáze: | MEDLINE |
| Externí odkaz: |
|